Atlas helps R&D teams evaluate therapeutic targets, emerging modalities, competitive pipelines, and scientific evidence with structured, publication-ready intelligence reports.
R&D teams are expected to answer questions like these every week. Yet the answers are scattered across publications, patents, conference abstracts, clinical trials, company disclosures, and regulatory filings.
Atlas brings those sources together into structured intelligence reports that support research strategy, not just literature collection.
Four report types, one structured pipeline, grounded in scientific and commercial evidence.
Map disease biology, therapeutic modalities, clinical activity, emerging science, and commercial development.
Benchmark competitors across pipelines, publications, partnerships, licensing activity, and clinical progress.
Structured evidence synthesis using rigorous search methodology and publication-ready citations.
Evaluate external companies, platform technologies, partnerships, and scientific positioning.
You stay in control at every checkpoint. Atlas pauses for your sign-off before research begins, before writing starts, and before delivery.
Atlas is not a black box. Every stage has a structured checkpoint where you review what the system has done, edit if needed, and explicitly sign off before the next phase begins.
Evaluate biological rationale, competitive activity, and translational evidence before investing.
Understand where a disease area is evolving and where opportunities remain.
Compare emerging scientific approaches, including efficacy, maturity, and commercial activity.
Track competitor assets from preclinical through late-stage development.
Rapidly assess external technologies, licensing opportunities, and partnerships.
Transform hundreds of publications into a structured evidence review.
Evaluate the competitive landscape for GLP-1 combination therapies.
Map emerging in vivo gene editing delivery technologies.
Review evidence supporting TIGIT inhibition across solid tumors.
Compare next-generation antibody-drug conjugate platforms.
Landscape companies developing RNA editing therapeutics.
Assess therapeutic approaches targeting NLRP3 inflammasome inhibition.
Publications alone don't tell the whole story. Atlas connects scientific evidence with companies, funding, partnerships, and competitive activity.
Every report follows the same transparent research process, from scope to delivery.
Review checkpoints before research, writing, and delivery keep you in control throughout.
Reports executives, project teams, and governance committees can immediately use.
Connect your internal document repository and Atlas cites your materials alongside public research, automatically, at every stage of the pipeline.
Talk to usWhether you're evaluating a therapeutic target, reviewing emerging science, assessing competitors, or preparing an evidence review, Atlas helps your team move from research question to decision-ready intelligence in hours.
Start Research